Increasing resistance to presently
available antimalarial drugs
urges the need to look for new promising compounds. The β-carboline
moiety, present in several biologically active natural products and
drugs, is an important scaffold for antimalarial drug discovery. The
present study explores the antimalarial activity of a β-carboline
derivative (1
R
,3
S
)-methyl 1-(benzo[
d
][1,3]dioxol-5-yl)-2,3,4,9-tetrahydro-1
H
-pyrido[3,4-
b
]indole-3-carboxylate (
9a
) alone
in vitro
against
Plasmodium
falciparum
and
in vivo
in combination
therapy with the standard drug artesunate against
Plasmodium
berghei
. Compound
9a
inhibited both 3D7
and RKL-9 strains of
P. falciparum
with
half-maximal inhibitory concentration (IC
50
) < 1 μg/mL,
respectively. The compound was nontoxic (50% cytotoxic concentration
(CC
50
) > 640 μg/mL) to normal dermal fibroblasts.
Selectivity index was >10 against both the strains. The compound
exhibited
considerable
in vivo
antimalarial activity (median
effective dose (ED
50
) = 27.74 mg/kg) in monotherapy. The
combination of
9a
(100 mg/kg) and artesunate (50 mg/kg)
resulted in 99.69% chemosuppression on day 5 along with a mean survival
time of 25.8 ± 4.91 days with complete parasite clearance. Biochemical
studies indicated the safety of the HIT compound to hepatic and renal
functions of mice. Molecular docking also highlighted the suitability
of
9a
as a potential antimalarial candidate.